Webinar Includes : All the training handouts , certificate ,Q/A and 90 mins Live WebinarTraining Overview
The current pandemic has turned the global focus on the issues surrounding the patenting and protection of COVID-19 vaccines, drugs, and other treatments. On the one hand, companies and institutions developing these treatments want to protect their innovations. Like other patent claims, compound, composition, and method claims for vaccines must have novel, non-obvious, and useful properties. They may also include multiple layers of patents from formulations to manufacturing to methods of use. On the other hand, public interest in getting access to vaccines is at an all-time high. Issues such as compulsory licensing, march-in rights, and IP waivers have all been mentioned in helping countries get access to treatments and avoid infringement. This presentation will discuss not only the global patenting issues facing vaccines but will also look at some of the challenges facing vaccine patenting.Why Should You Attend
To understand the intellectual property and patent issues surrounding the developing of COVID-19 vaccines and treatments.Webinar Takeaway
C-level executives in companies developing vaccines
Anyone interested in understanding the current situation surrounding the development of COVID-19 vaccinesJoanna Brougher
Life Sciences IP attorney for Entrepreneurs and Start-ups, Educator, International Speaker, and Author
Joanna is a patent attorney who focuses her practice on all aspects of services related to patents in the areas of biotechnology, pharmaceuticals and medical devices, including patentability opinions, patent drafting, domestic and foreign patent prosecution, development and management of patent portfolios, and general client counseling during all phases of a product’s lifecycle, from concept to commercialization
Joanna’s patent experience covers a variety of complex and innovative inventions involving small molecule drugs, biologics, cell-based technologies, compositions, drug formulations and drug delivery systems, immunotherapeutics, medical devices, diagnostic tests, and immunology, particularly vaccines and antibodies. Joanna also has experience counseling clients on the Hatch-Waxman Act and is monitoring developments involving biosimilars under the Biologics Price Competition and Innovation Act.